Application of mizoribine in treatment of cerebral apoplexy
By administering mizoribine via inhalation, a lung-targeted formulation was developed, addressing the issues of immune cell infiltration and inflammation in the treatment of ischemic stroke, achieving significant neurological function recovery and a high level of safety.
Patent Information
- Application Number
- CN202511382448.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-25
- Publication Date
- 2025-11-14
AI Technical Summary
There is a lack of effective drugs for treating ischemic stroke in the current technology, especially drugs with low safety and efficacy, which are difficult to effectively inhibit the infiltration of brain immune cells and reduce inflammation, thus affecting the patient's prognosis.
Using mizoribine as the drug, it is administered via inhalation to form lung-targeted formulations or inhalers, including aerosols, sprays, and inhaled liquid formulations, which act directly on the lungs to enhance drug accumulation in the brain, inhibit immune cell infiltration and reduce inflammation, and improve neurological function.
It significantly reduces the infarct area of ischemic stroke, inhibits brain inflammation, promotes the recovery of neurological function, improves motor and sensory function, has low toxicity and high safety, and has significant therapeutic effects.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the pharmaceutical field, specifically to the treatment of stroke with imidazolidin. Background Technology
[0002] Stroke is a serious cerebrovascular disease that causes permanent disability and death. It is mainly caused by the sudden rupture of blood vessels in the brain or by vascular obstruction, preventing blood from flowing to the brain and causing brain tissue damage. Stroke is characterized by high incidence, high disability rate, high recurrence rate, and poor prognosis, seriously threatening human life and health. Pathologically, stroke can be divided into two main categories: ischemic stroke and hemorrhagic stroke. Ischemic stroke refers to a local obstruction of blood supply to a specific area of brain tissue, leading to ischemic and hypoxic necrosis of brain tissue, which in turn produces corresponding neurological deficits. Typical characteristics include abnormal activation of microglia, production of inflammatory cytokines, and infiltration of immune cells. These mechanisms collectively exacerbate ischemic brain damage, severely affecting the patient's prognosis.
[0003] Prevention and treatment of cerebral ischemia-reperfusion injury is a key and challenging aspect of the clinical treatment of ischemic stroke. Currently, one type of molecule under investigation for ischemic stroke is a neuroprotective agent, which is used to prevent and treat sequelae of ischemic stroke and reduce mortality.
[0004] Mizoribine is approved for the treatment of rejection reactions during kidney transplantation, but there are currently no literature reports on its use in the treatment of ischemic stroke. Summary of the Invention
[0005] Some embodiments of this invention have revealed that inhaled administration of mizoribine to treat acute ischemic stroke effectively enhances mizoribine accumulation in the lungs, reduces the infarct area, inhibits immune cell infiltration in the brain, alleviates inflammation at the stroke site in the brain parenchyma, and improves stroke-related neurological function, including sensory and / or motor dysfunction. For example, improved neurological function includes mitigating neurological damage at the stroke site and promoting the recovery of damaged nerve function. This invention's inhaled administration of mizoribine to treat ischemic stroke has the advantages of significant efficacy, low toxicity, good stability, and high safety, and shows outstanding potential for the development of novel immune cell inhibitors for the treatment of brain diseases.
[0006] Furthermore, mizoribine can be formulated into lung-targeted preparations or inhalers containing an effective amount of mizoribine, which in this art means that mizoribine monotherapy is effective in treating ischemic stroke. The preparations can be powders or liquids, and inhalers can be oral, nasal, or both oral and nasal inhalers, where inhalation occurs through both the mouth and nose. Types of inhalers include aerosols, sprays, inhaled liquid preparations, powder inhalers, or vaporizable preparations.
[0007] As a further improvement, the inhaler includes an isotonic modifier, such as NaCl, which can be nebulized for delivery. Attached Figure Description
[0008] Figure 1 TTC-stained images of rat brain slices from different groups in Example 1 of this invention and semi-quantitative analysis (where **** represents P<0.0001);
[0009] Figure 2 The neurological function scores of MCAO rats in Example 1 of this invention are shown below (where A is the Langer score, B and C are the sticky tag test, and **** represents P<0.0001).
[0010] Figure 3 The results of immunofluorescence staining of CD45-positive cells (i.e., immune cells) in different groups of rat brain tissue in Example 1 of this invention.
[0011] The grouping labels in each figure follow a unified principle. In this paper, the Sham group refers to the separately set sham surgery group, while the other groups are the treatment groups that were treated with the test substance on MCAO model mice. Detailed Implementation
[0012] The applicant's research has found that mizoribine can inhibit the infiltration of immune cells in the brain, reduce inflammation at the stroke site in the brain parenchyma, improve neurological damage at the stroke site, promote the recovery of damaged nerve function, and reduce the infarct area. This invention also reveals that inhaled mizoribine can enhance drug accumulation in the lungs, demonstrating that oral and nasal inhalation of mizoribine has significant effects, low toxicity, and high safety in the treatment of ischemic stroke.
[0013] The present invention will be further described below with reference to specific embodiments, but the scope of protection of the present invention is not limited thereto; modifications or substitutions to the details and form of the present invention may be made without departing from the spirit and scope of the present invention, but such modifications and substitutions all fall within the scope of protection of the present invention. Unless otherwise specified, the experimental methods in the following embodiments are conventional methods; unless otherwise specified, the experimental materials used in the following embodiments are conventional materials or can be purchased from biochemical reagent manufacturers.
[0014] Example 1: Pharmacodynamic effect of intranasal and oral imidazolidin on ischemic stroke model in SD rats
[0015] 1. Experimental Materials
[0016] (1) Drugs
[0017] Preparation method: Dissolve 1.8 mg of imidazolidin in 2 mL of physiological saline, sonicate for 10 min to form an aqueous solution, and place it in a nebulizer to form nebulized droplets.
[0018] (2) Laboratory animals
[0019] SD rats, 6-8 weeks old, male.
[0020] 2. Experimental Methods
[0021] Animals were kept between 230-260g in weight and fasted overnight before model establishment, but were allowed normal water intake.
[0022] (1) Rat anesthesia
[0023] Rats were anesthetized by intraperitoneal injection of 2.6 mL of Avertin (10 uL / g).
[0024] (2) Surgery
[0025] The skin around the neck was cut open, and the neck muscles were bluntly dissected to expose the left common carotid artery and the internal and external carotid arteries of the rat. The common carotid artery was dissected, and the external carotid artery, suboccipital artery, and internal carotid artery were sequentially separated distally. Double sutures were threaded through the external carotid and suboccipital arteries for later use. The internal carotid artery and pterygopalatine artery were dissected, and the pterygopalatine artery was ligated with a vascular clamp, keeping the internal carotid artery, the only branch of the common carotid artery, open. After ligating the external carotid and suboccipital arteries with double sutures, the vessels were cut, and a loose knot was made in the external carotid artery for later use. The proximal end of the common carotid artery and the internal carotid artery were clamped with an arterial clamp. A 45° incision was made in the external carotid artery, and a suture plug was inserted towards the neck to secure it. The arterial clamp was then released. A silicone-coated suture plug was carefully inserted from the external carotid artery into the internal carotid artery, all the way to the origin of the middle cerebral artery. An appropriate suture plug was selected based on the size of the experimental animal and the required head diameter.
[0026] (3) Reinfusion
[0027] Pull out the suture, allowing the head end to retract to the external carotid artery. Do not pull it out completely to avoid arterial rupture and bleeding. Ligate the stump of the external carotid artery, allowing blood flow from the common carotid artery to re-perfuse into the middle carotid artery. Suture the wound skin and return the animal to its cage after it has recovered from anesthesia.
[0028] (4) Postoperative care and vital sign monitoring
[0029] The room temperature should be maintained at 25℃, and attention should be paid to animal protection during and after the operation, as well as postoperative care.
[0030] (5) Grouping of experimental animals
[0031] After suturing and reperfusion, the animals were randomly divided into groups. Immediately after grouping, the drugs were administered via injection in the lower abdomen or via nebulizer according to the administration protocol shown in Table 1. TTC staining was performed 24 hours after administration to evaluate the therapeutic effects of different drug administration groups.
[0032] Table 1 Grouping of experimental animals for drug administration
[0033]
[0034] Note: The difference between the sham group and the Saline group is that the blood vessels of the mice in the sham group did not suffer from embolism caused by MCAO surgery; the other groups are experimental groups that were treated with drugs in MCAO model mice with cerebral ischemia-reperfusion injury.
[0035] 3. Evaluation Indicators
[0036] (1) TTC staining to evaluate infarct volume
[0037] 1) Decapitation and brain removal: After anesthetizing the rat, it was euthanized and the intact brain tissue was removed;
[0038] 2) After rinsing the brain tissue in physiological saline, freeze it in a -80℃ freezer for 10 minutes;
[0039] 3) After freezing, cut the brain tissue into 6 even slices;
[0040] 4) Immerse the brain slices completely in 2% 2,3,5-triphenyltetrazolium (TTC) staining solution (prepared with PBS), and incubate in a 37°C incubator in the dark for 20 minutes. Gently shake the container every 5 minutes to ensure the brain slices are fully stained.
[0041] 5) Remove brain slices, arrange them neatly in order, take photos for record-keeping, and stain with TTC;
[0042] 6) Image analysis was performed using ImageJ 1.53 and GraphPad Prism 8.0. The infarct area and total area of each slice were measured, and the data were statistically analyzed. The results are as follows: Figure 1 As shown.
[0043] (2) Neurological function score
[0044] The Longa scoring system was used to assess the neurological function of rats. The specific scoring criteria are as follows:
[0045] 0 points: The rat showed no neurological damage and behaved normally.
[0046] 1 point: After lifting the rat by its tail, the forelimb on the opposite side of the operation could not be fully extended.
[0047] 2 points: When the rat walks independently, it circles towards the side opposite to the surgery.
[0048] 3 points: When the rat was walking independently, its body tilted towards the side opposite to the surgery.
[0049] 4 points: The rat was unable to walk on its own and lost consciousness.
[0050] 5 points: Death
[0051] After the administration of the drug, according to the above scoring criteria, lift the rat by the tail and observe the extension of the rat's forelimb on the opposite side of the surgery. Then place it on a horizontal surface and observe whether it walks in circles. The rat's neurological function is scored.
[0052] (3) Behavioral evaluation
[0053] 1) The behavior of rats was evaluated by the sticky tag test. The rats were trained to perform the sticky tag test 3 days before the MCAO model was established, 3 times a day. The experiment was carried out after the MCAO model was established and the drugs were administered.
[0054] 2) Apply a 13×13mm patch to the back of the rat's paw. 2 The rats were given adhesive tags as tactile stimuli, and then returned to their cages. The time it took for the rats to come into contact with and remove the adhesive tags was recorded.
[0055] (4) Investigation of immune cell infiltration in rat brain tissue
[0056] 1) After treatment, the SD rats were euthanized, and the rat brain tissue was washed with PBS solution.
[0057] 2) The brain tissue was fixed by immersing it in a tissue fixation solution. After fixation, the brain tissue was sectioned in paraffin and dewaxed and antigens were removed.
[0058] 3) Add blocking solution and incubate at room temperature for 1 hour to block non-specific binding sites;
[0059] 4) Discard the blocking solution, add CD45 antibody diluted as required (1:500) to the tissue surface, and incubate overnight at 4°C in the dark;
[0060] 5) Wash the tissue sample three times with PBS solution to remove unbound antibodies;
[0061] 6) Add fluorescently labeled secondary antibody and incubate in the dark for 90 min;
[0062] 7) Add DAPI staining solution and incubate in the dark for 15 minutes;
[0063] 8) Add anti-fluorescence quencher to complete the mounting process;
[0064] 9) Use a laser scanning confocal microscope to photograph and acquire images of tissue samples.
[0065] Experimental results:
[0066] TTC staining was performed on the infarcted area to quantitatively assess the neuroprotective effect of intranasal and oral inhalation of imidazolidin. Figure 1It can be seen that after treatment with inhaled imidazolidin via the mouth and nose, the infarct area of MCAO rats decreased significantly compared to the Saline group.
[0067] The recovery of neurological function in rats after treatment was assessed using neurological function scoring and a sticky tag test. Specific results are as follows: Figure 2 As shown in the figure, compared with the Saline group, the neurological function scores of MCAO rats treated with nasal and oral inhalation of mizoribine were significantly reduced, indicating that nebulized mizoribine has a significant therapeutic effect in improving neurological function. Furthermore, in the stick test, which assessed skin sensitivity and sensory integration, the time taken for MCAO rats to contact and remove the stick was significantly shorter in the stick test compared with the Saline group. This suggests that nasal and oral inhalation of mizoribine after stroke can promote the improvement of sensorimotor function in rats.
[0068] Immunofluorescence staining results as follows Figure 3 As shown in the figure, compared with the Saline group, the number of immune cells in the stroke site was significantly reduced after oral and nasal inhalation of mizoribine, indicating that oral and nasal inhalation of mizoribine effectively inhibited the infiltration of immune cells after stroke, thereby reducing inflammation in the brain.
Claims
1. An inhaled medication for the treatment of ischemic stroke, containing an effective amount of mizoribine.
2. The inhalant as claimed in claim 1, characterized in that, The inhalant is an aerosol, spray, inhaled liquid preparation, powder inhaler, or a vapor-convertible preparation.
3. The inhalant as claimed in claim 1, characterized in that, The inhalant is a powder or a liquid.
4. The inhalant as claimed in claim 1, characterized in that, The inhaler contains an isotonic modifier.
5. The inhalant as claimed in any of the prior claims, characterized in that, The inhaler contains NaCl.
6. Use of the inhalation formulation of imidazolidin or any of the prior claims in the preparation of a medicament for the treatment of ischemic stroke.
7. The application as described in claim 6, characterized in that, The drug is used to reduce the infarct area of stroke, alleviate inflammation at the stroke site in the brain parenchyma, and / or improve stroke-related neurological function.
8. The application as described in claim 7, characterized in that, The improvement of stroke-related neurological function includes improving neurological damage at the stroke site and / or promoting the recovery of damaged nerve function.
9. The application as described in any of the prior claims, characterized in that, The stroke mentioned is an acute ischemic stroke.
